Uptake of bone modifying agents in patients with HER2 metastatic breast cancer with bone metastases - prospective data from a multi-site Australian registry.
Vanessa Wong, Richard de Boer, Catherine Dunn, Angelyn Anton, Laeeq Malik, Sally Greenberg, Belinda Yeo, Louise Nott, Ian M Collins, Javier Torres, Frances Barnett, Michelle Nottage, Peter Gibbs, Sheau Wen Lok
Intern Med J | Published : 2021
BACKGROUND AND AIM: International practice guidelines recommend administration of bone modifying agents (BMA) in metastatic breast cancer (MBC) patients with bone metastases to reduce skeletal related events (SRE). Optimal delivery of BMA in routine clinical practice including agent selection and prescribing intervals remains unclear. We aim to describe real-world practice of Australian breast oncologists. METHODS: Prospective data from February 2015 to July 2020 on BMA delivery to MBC patients with bone metastases was analysed from TABITHA, a multi-site Australian HER2+ MBC registry. RESULTS: Of 333 HER2+ MBC patients, 171 (51%) had bone metastases at diagnosis, with a mean age of 58.1 year..View full abstract